CDC25 phosphatases in cancer cells: Key players? Good targets?

Nature Reviews Cancer

Volumn 7, Issue 7, 2007, Pages 495-507

  Boutros, Rose ^a   Lobjois, Valérie ^a   Ducommun, Bernard ^a,b  

^a Institut d'Exploration Fonctionnelle des Genomes   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ADOCIAQUINONE B; ANTINEOPLASTIC AGENT; BN 82685; DOXORUBICIN; DYSIDIOLYDE; FLAVOPIRIDOL; IRC 083864; JUN 1111; KR 61170; NSC 663284; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; ROSCOVITINE; UNCLASSIFIED DRUG; XL 844;

APOPTOSIS; BINDING AFFINITY; BINDING SITE; CANCER; CANCER CELL; CARCINOGENESIS; CELL CYCLE; CELL CYCLE REGULATION; CELL DIVISION; CELL PROLIFERATION; CLINICAL TRIAL; DNA DAMAGE; GENE MUTATION; GENETIC STABILITY; GENOMIC INSTABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; CDC25 PHOSPHATASE; CELL CYCLE; CELL DIVISION; EVOLUTION, MOLECULAR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PHYLOGENY;

EID: 34250865564     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2169     Document Type: Review

References (164)

1. Boudolf, V., Inze, D. & De Veylder, L. What if higher plants lack a CDC25 phosphatase? Trends Plant Sci. 11, 474-479 (2006).
2. Galaktionov, K. & Beach, D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 67, 1181-1194 (1991).
3. Sadhu, K., Reed, S. I., Richardson, H. & Russell, P. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Proc. Natl Acad. Sci. USA 87, 5139-5143 (1990).
4. + gene and also the first report of CDC25 overexpression in cancer cell lines.
5. Izumi, T. & Maller, J. L. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol. Cell Biol. 4, 1337-1350 (1993).
6. Okazaki, K. et al. Isolation of a cDNA encoding the xenopus homologue of mammalian Cdc25A that can induce meiotic maturation of oocytes. Gene 178, 111-114 (1996).
7. Benazeraf, B. et al. Identification of an unexpected link between the Shh pathway and a G2/M regulator, the phosphatase CDC25B. Dev. Biol. 294, 133-147 (2006).
8. Wegener, S., Hampe, W., Herrmann, D. & Schaller, H. C. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur. J. Cell Biol. 79, 810-815. (2000).
9. Baldin, V., Cans, C., Superti-Furga, G. & Ducommun, B. Alternative splicing of the human CDC25B tyrosine phoshatase. Possible implications for growth control? Oncogene 14, 2485-2495 (1997). The first report that multiple CDC25B variants derive from a single mRNA by alternative splicing events.
10. Forrest, A. R. et al. Multiple splicing variants of cdc25B regulate G2/M progression. Biochem. Biophys. Res. Commun. 260, 510-515 (1999).
11. Bureik, M. et al. An additional transcript of the cdc25C gene from A431 cells encodes a functional protein. Int. J. Oncol. 17, 1251-1258. (2000).
12. Russell, P. & Nurse, P. cdc25 + functions as an inducer in the mitotic control of fission yeast. Cell 45, 145-153 (1986).
13. Malumbres, M. & Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30, 630-641 (2005).
14. Kaldis, P. The cdk-activating kinase (CAK): from yeast to mammals. Cell Mol. Life Sci. 55, 284-296 (1999).
15. Kristjansdottir, K. & Rudolph, J. Cdc25 phosphatases and cancer. Chem. Biol. 11, 1043-1051 (2004). A comprehensive review on the different methods used to detect CDC25 overexpression in human cancer.
16. Blomberg, I. & Hoffmann, I. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol. Cell Biol. 19, 6183-6194 (1999).
17. Hoffman, I., Draetta, I. & Karsenti, G. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 13, 4302-4310 (1994).
18. Jinno, S. et al. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13, 1549-1556 (1994).
19. Molinari, M., Mercurio, C., Dominguez, J., Goubin, F. & Draetta, G. F. Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep. 1, 71-79. (2000).
20. Zhao, H., Watkins, J. L. & Piwnica-Worms, H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc. Natl Acad. Sci. USA 99, 14795-14800 (2002).
21. Lindqvist, A., Kallstrom, H., Lundgren, A., Barsoum, E. & Rosenthal, C. K. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. J. Cell Biol. 171, 35-45 (2005). An important study exploring the relative roles of CDC25A and CDC25B in inducing mitotic onset. The authors show that CDC25B is required for the initial activation of CDK1-cyclin B at the centrosomes, whereas CDC25A is involved in chromatin condensation.
22. Mailand, N. et al. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J. 21, 5911-5920 (2002).
23. Boutros, R., Dozier, C. & Ducommun, B. The when and wheres of CDC25 phosphatases. Curr. Opin. Cell Biol. 18, 185-191 (2006). A detailed review of the complex mechanisms that regulate CDC25 activities throughout the cell cycle.
24. Millar, J. et al. p55 cdc25 is a nuclear phosphoprotein required for the initiation of mitosis in human cells. Proc. Natl Acad. Sci. USA 88, 10500-10504 (1991).
25. Lammer, C. et al. The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J. Cell Sci. 111, 2445-2453 (1998).
26. Gabrielli, B. G. et al. Cytoplasmic accumulation of CDC25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J. Cell Sci. 109, 1081-1093 (1996). The first demonstration of a link between cytoplasmic CDC25B accumulation and centrosomal events that occur during the G2-M transition.
27. De Souza, C. P., Ellem, K. A. & Gabrielli, B. G. Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp. Cell Res. 257, 11-21 (2000).
28. Gabrielli, B. G., Clarck, J. M., McCormack, A. & Ellem, K. A. O. Hyperphosphorylation of the N-terminal domain of cdc25 regulates activity toward cyclinB1/cdc2 but not cyclin A/cdk2. J. Biol. Chem. 272, 28607-28614 (1997).
29. Turowski, P. et al. Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol. Biol. Cell 14, 2984-2998 (2003).
30. Garner-Hamrick, P. A. & Fischer, C. Antisense phosphoorthioate oligonucleotides specifically down-regulate cdc25B causing S-phase delay and persitent antiproliferative effects. Int. J. Cancer 76, 720-728 (1998).
31. Ferguson, A. M., White, L. S., Donovan, P. J. & Piwnica-Worms, H. Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol. Cell Biol. 25, 2853-2860 (2005). An important study in which the authors challenge the idea that all three CDC25 isoforms are required for normal cell-cycle progression, by successfully generating mice that lack both CDC25B and CDC25C without any obvious defects in cell-cycle function or checkpoint responses.
32. -/- female mice are sterile because of permanent meiotic arrest, resulting from lack of maturation promoting factor (MPF; CDK1-cyclinB1 complex) activity.
33. Karlsson-Rosenthal, C. & Millar, J. B. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol. 16, 285-292 (2006).
34. Cazales, M. et al. CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle 4, 1233-1238 (2005).
35. Dutertre, S. et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2/M transition. J. Cell Sci. 117, 2523-2531 (2004). This study demonstrates that phosphorylation by Aurora A is required for CDC25B activity and localization to the centrosomes to initiate mitotic entry.
36. Theis-Febvre, N. et al. Protein kinase CK2 regulates CDC25B phosphatase activity. Oncogene 22, 220-232 (2003).
37. Hoffmann, I., Clarke, P., Marcote, M. J., Karsenti, E. & Draetta, G. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self amplification of MPF at mitosis. EMBO J. 12, 53-63 (1993).
38. Barr, F. A., Sillje, H. H. & Nigg, E. A. Polo-like kinases and the orchestration of cell division. Nature Rev. Mol. Cell Biol. 5, 429-440 (2004).
39. Karaiskou, A., Jessus, C., Brassac, T. & Ozon, R. Phosphatase 2A and polo kinase, two antagonistic regulators of cdc25 activation and MPF autoamplification. J Cell Sci. 112, 3747-3756 (1999).
40. Kumagaï, A. & Dunphy, W. G. Purification and molecular cloning of Plx1, a Cdc25-reg ulatory kinase from Xenopus egg extracts. Science 273, 1377-1380 (1996).
41. Qian, Y. W., Erikson, E., Li, C. & Maller, J. L. Activated polo-like kinase Plx1 is required at multiple points during mitosis in Xenopus laevis. Mol. Cell Biol. 18, 4262-4271 (1998).
42. Roshak, A. K. et al. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal. 12, 405-411 (2000).
43. Myer, D. L., Bahassi el, M. & Stambrook, P. J. The Plk3-Cdc25 circuit. Oncogene 24, 299-305 (2005).
44. Toyoshima-Morimoto, F., Taniguchi, E. & Nishida, E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep. 3, 341-348 (2002).
45. Hermeking, H. & Benzinger, A. 14-3-3 proteins in cell cycle regulation. Semin. Cancer Biol. 16, 183-192 (2006).
46. Davezac, N. et al. Regulation of CDC25B phosphatases subcellular localization. Oncogene 19, 2179-2185 (2000).
47. Loffler, H. et al. Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 1 November 2006 (Epub ahead of print).
48. Mils, V. et al. Specific interaction between 14. 3. 3 isoforms and the human CDC25B phosphatase. Oncogene 19, 1257-1265 (2000).
49. Sanchez, Y. et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497-1501 (1997).
50. Kramer, A. et al. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nature Cell Biol. 6, 884-891 (2004). An interesting study in which CHK1 is reported to localize to the centrosomes of interphase cells, and this pool of CHK1 functions to prevent the premature activation of CDK1-cyclin B.
51. Schmitt, E. et al. CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage. J. Cell Sci. 119, 4269-4275 (2006). This study shows that CHK1 phosphorylates CDC25B in vitro and in vivo during interphase in the absence of DNA damage, in order to inhibit its mitosis-inducing activity.
52. Mirey, G. et al. CDC25B phosphorylated by pEg3 localizes to the centrosome and the spindle poles at mitosis. Cell Cycle 4, 806-811 (2005).
53. Chen, M. S., Ryan, C. E. & Piwnica-Worms, H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol. Cell Biol. 23, 7488-7497 (2003).
54. Donzelli, M. et al. Dual mode of degradation of Cdc25 A phosphatase. EMBO J. 21, 4875-4884 (2002).
55. Busino, L., Chiesa, M., Draetta, G. F. & Donzelli, M. Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23, 2050-2056 (2004).
56. Busino, L. et al. Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature 426, 87-91 (2003).
57. Jin, J. et al. SCFβ-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 17, 3062-3074 (2003).
58. Donzelli, M. et al. Hierarchical order of phosphorylation events commits Cdc25A to βTrCP-dependent degradation. Cell Cycle 3, 469-471 (2004).
59. Baldin, V., Cans, C., Knibiehler, M. & Ducommun, B. Phosphorylation of human CDC25B phosphatase by CDK1/cyclin A triggers its proteasome-dependent degradation. J. Biol. Chem. 272, 32731-32735 (1997).
60. Kanemori, Y., Uto, K. & Sagata, N. β-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc. Natl Acad. Sci. USA 102, 6279-6284 (2005).
61. Hurley, P. J. & Bunz, F. ATM and ATR: components of an integrated circuit. Cell Cycle 6, 414-417 (2007).
62. Niida, H. & Nakanishi, M. DNA damage checkpoints in mammals. Mutagenesis 21, 3-9 (2006).
63. Goloudina, A. et al. Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle 2, 473-478 (2003).
64. Xiao, Z. et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem. 278, 21767-21773 (2003).
65. Mailand, N. et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425-1429 (2000).
66. Sorensen, C. S. et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3, 247-258 (2003).
67. Matsuoka, S., Huang, M. & Elledge, S. J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893-1897 (1998).
68. Peng, C. Y. et al. Mitotic and G2 checkpoint control: regulation of 14. 3. 3 protein binding by phosphorylation of CDC25C on Serine-216. Science 277, 1501-1505 (1997).
69. Yarden, R. I., Pardo-Reoyo, S., Sgagias, M., Cowan, K. H. & Brody, L. C. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nature Genet. 30, 285-289 (2002).
70. Raleigh, J. M. & O'Connell, M. J. The G(2) DNA damage checkpoint targets both Wee1 and Cdc25. J. Cell Sci. 113, 1727-1736 (2000).
71. Mikhailov, A., Shinohara, M. & Rieder, C. L. The p38-mediated stress-activated checkpoint. A rapid response system for delaying progression through antephase and entry into mitosis. Cell Cycle 4, 57-62 (2005).
72. Bulavin, D. V. et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411, 102-107 (2001). The first study to show the essential role of the p38 kinase in the G2/M checkpoint response to UV radiation, by the phosphorylation of both CDC25B and CDC25C, and by the inhibition of 14-3-3 binding in the case of CDC25B.
73. Lemaire, M. et al. CDC25B Phosphorylation by p38 and MK-2. Cell Cycle 5, 1649-1653 (2006).
74. Manke, I. A. et al. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell 17, 37-48 (2005).
75. Reinhardt, H. C., Aslanian, A. S., Lees, J. A. & Yaffe, M. B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2pathway for survival after DNA damage. Cancer Cell 11, 175-189 (2007). A very interesting study in which the p38-MAPKAPK2 pathway was shown to function as an alternative checkpoint response to UV in p53-deficient tumour cells, and to be directly activated by DNA-damaging chemotherapeutic agents.
76. van Vugt, M. A., Bras, A. & Medema, R. H. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol. Cell 15, 799-811 (2004). In this study, the authors show that although PLK1 is not an essential kinase for mitotic entry in undamaged cells, it becomes indispensable along with CDC25B, for the recovery of G2/M checkpoint arrest after DNA damage.
77. Bugler, B. et al. Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol. Cancer Ther. 5, 1446-1451 (2006).
78. Bansal, P. & Lazo, J. S. Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res. 67, 3356-3363 (2007).
79. Cangi, M. G. et al. Role of the Cdc25A phosphatase in human breast cancer. J. Clin. Invest. 106, 753-761 (2000).
80. Bonin, S., Brunetti, D., Benedetti, E., Gorji, N. & Stanta, G. Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and postmenopausal breast cancer. Virchows Arch. 448, 539-544 (2006).
81. Ito, Y. et al. Expression of cdc25A and cdc25B phosphatase in breast carcinoma. Breast Cancer 11, 295-300 (2004).
82. Galaktionov, K. et al. Cdc25 phosphatases as potential human oncogenes. Science 269, 1575-1577 (1995). This study was the first report of overexpression of CDC25B in primary tissue samples from human breast cancer, and also the first to associate this overexpression with a higher tumour grade.
83. Broggini, M. et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 20, 4835-4840 (2000).
84. Ngan, E. S., Hashimoto, Y., Ma, Z. Q., Tsai, M. J. & Tsai, S. Y. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 22, 734-739 (2003).
85. Ozen, M. & Ittmann, M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin. Cancer Res. 11, 4701-4706 (2005).
86. Sasaki, H. et al. Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer. Cancer Lett. 173, 187-192 (2001).
87. Wu, W., Fan, Y. H., Kemp, B. L., Walsh, G. & Mao, L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 58, 4082-4085 (1998).
88. Takemasa, I. et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res. 60, 3043-3050 (2000).
89. Hernandez, S. et al. Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab. Invest. 81, 465-473 (2001).
90. Talvinen, K. et al. Biochemical and clinical approaches in evaluating the prognosis of colon cancer. Anticancer Res. 26, 4745-4751 (2006).
91. Hu, Y. C., Lam, K. Y., Law, S., Wong, J. & Srivastava, G. Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin. Cancer Res. 7, 2213-2221 (2001).
92. Miyata, H. et al. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin. Cancer Res. 6, 4859-4865 (2000).
93. Nishioka, K. et al. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br. J. Cancer 85, 412-421 (2001).
94. Kishi, K. et al. Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br. J. Surg. 89, 597-603 (2002).
95. Sunada, F., Itabashi, M., Ohkura, H. & Okumura, T. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World J. Gastroenterol. 11, 5696-5700 (2005).
96. Ito, Y. et al. Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation. Int. J. Mol. Med. 13, 431-435 (2004).
97. Ito, Y. et al. Expression of cdc25A and cdc25B proteins in thyroid neoplasms. Br. J. Cancer 86, 1909-1913 (2002).
98. Ito, Y. et al. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. Cancer Lett. 229, 291-297 (2005).
99. Fraczek, M., Wozniak, Z., Ramsey, D. & Krecicki, T. Expression patterns of cyclin E, cyclin A and CDC25 phosphatases in laryngeal carcinogenesis. Eur. Arch. Otorhinolaryngol. 2007 (doi:10-1007/s00405- 007-0276-2)
100. Xu, X. et al. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin. Cancer Res. 9, 1764-1772 (2003).
101. Kudo, Y. et al. Overexpression of cyclin-dependent kinase activating CDC25B phosphatase in human gastric carcinomas. Jpn J. Cancer Res. 88, 947-952 (1997).
102. Guo, J. et al. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 23, 71-81 (2004).
103. Wu, W. et al. Coordinate expression of Cdc25B and ER-α is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res. 63, 6195-6199 (2003).
104. Tsuda, H., Hashiguchi, Y., Inoue, T. & Yamamoto, K. Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology 65, 159-166 (2003).
105. Gasparotto, D. et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 57, 2366-2368 (1997).
106. Sato, Y. et al. Expression of the cdc25B mRNA correlated with that of N-myc in neuroblastoma. Jpn J. Clin. Oncol. 31, 428-431 (2001).
107. Nakabayashi, H., Hara, M. & Shimizu, K. Prognostic significance of CDC25B expression in gliomas. J. Clin. Pathol. 59, 725-728 (2006).
108. Hernandez, S. et al. CDC25 cell cycle-activating phosphatases and c-myc expresion in human non-hodgkin's lymphomas. Cancer Res. 58, 1762-1767 (1998).
109. Hernandez, S. et al. cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or-C, are overexpressed in aggressive human non-Hodgkin's lymphomas. Int. J. Cancer 89, 148-152 (2000).
110. Moreira, G. Jr. et al. Reciprocal CDC25A and p27 expression in B-cell non Hodgkin lymphomas. Diagn. Mol. Pathol. 12, 128-132 (2003).
111. Aref, S. et al. c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma. Hematology 8, 183-190 (2003).
112. Nishioka, K. et al. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br. J. Cancer 85, 412-421 (2001).
113. Galaktionov, K., Chen, X. C. & Beach, D. Cdc25 cellcycle phosphatase as a target of c-myc. Nature 382, 511-517 (1996).
114. Ben-Yosef, T., Yanuka, O., Halle, D. & Benvenisty, N. Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene 17, 165-171 (1998).
115. Vigo, E. et al. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol. Cell Biol. 19, 6379-6395 (1999).
116. Wu, L. et al. E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression. Mol. Cell Biol. 20, 7059-7067 (2000).
117. Spitkovsky, D., Jansen-Dürr, P., Karsenti, E. & Hoffmann, I. S-phase induction by adenovirus E1A requires activation of cdc25A tyrosine phosphatase. Oncogene 12, 2549-2554 (1996).
118. Loffler, H. et al. Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines. Oncogene 22, 8063-8071 (2003).
119. Alderton, G. K. et al. Regulation of mitotic entry by microcephalin and its overlap with ATR signalling. Nature Cell Biol. 8, 725-733 (2006).
120. Gerstein, A. V. et al. APC/CTNNB1 (β-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34, 9-16 (2002).
121. He, N. et al. Regulation of lung cancer cell growth and invasiveness by β-TRCP. Mol. Carcinog. 42, 18-28 (2005).
122. Kim, C. J. et al. Somatic mutations of the β-TrCP gene in gastric cancer. Apmis 115, 127-133 (2007).
123. Bartek, J. & Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429 (2003).
124. Kim, S. O. et al. Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors. Cancer 101, 1018-1027 (2004).
125. Tort, F. et al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 19, 112-117 (2005).
126. Ray, D. et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 67, 984-991 (2007). In this study, the authors show that although transgenic expression of CDC25A alone is not sufficient to induce spontaneous tumour growth in mice, CDC25A overexpression generates genomic instability and cooperates with v-Ha-ras or c-neu oncogenes in murine mammary tumorigenesis.
127. Ma, Z. Q., Chua, S. S., DeMayo, F. J. & Tsai, S. Y. Induction of mammary gland hyperplasia in transgenic mice over- expressing human cdc25B. Oncogene 18, 4564-4576 (1999).
128. Yao, Y. et al. Increased susceptibility to carcinogen-induced mammary tumors in MMTV- Cdc25B transgenic mice. Oncogene 18, 5159-5166 (1999). References 127 and 128 discuss the effect of CDC25B overexpression in inducing mammary tumour growth. The expression of CDC25B alone promotes proliferation and hyperplasia but requires the presence of a carcinogen to stimulate tumour growth.
129. Karlsson, C., Katich, S., Hagting, A., Hoffmann, I. & Pines, J. Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J. Cell Biol. 146, 573-584 (1999).
130. Sexl, V. et al. A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene 18, 573-582 (1999).
131. Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J. & Lukas, J. The ATM-Chk2-CDC25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847. (2001).
132. Senderowicz, A. M. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr. Opin. Cell Biol. 16, 670-678 (2004).
133. Senderowicz, A. M. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog. Drug Res. 63, 183-206 (2005).
134. Byrd, J. C. et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109, 399-404 (2007).
135. Benson, C. et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer 96, 29-37 (2007).
136. Prevost, G. P. et al. in Progress in Cell Cycle Research (eds Meijer, L., Jézéquel, A. & Roberge, M.) 225-234 (Life in progress, Roscoff, France, 2003).
137. Lazo, J. S. et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J. Med. Chem. 44, 4042-4049 (2001). This study shows how the screening of a compound library coupled with experimental and computational approaches can result in the identification of a potent and specific CDC25 inhibitor.
138. Brisson, M. et al. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol. Pharmacol. 66, 824-833 (2004).
139. Cao, S., Foster, C., Brisson, M., Lazo, J. S. & Kingston, D. G. Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg. Med. Chem. 13, 999-1003 (2005).
140. Brezak, M. C. et al. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol. Cancer Ther. 4, 1378-1387 (2005). An important study reporting the identification of BN82685, a quinone-based potent CDC25 inhibitor. The fact that this compound inhibits the growth of xenografted human pancreatic tumours when orally administered highlights the value of CDC25 phosphatases as targets for anticancer therapeutics.
141. Galcera, M. O., Bigg, D., Prevost, G. & Sidhu, A. CDC25 phosphatases inhibitors. WO 2006/067311 (2006).
142. Kar, S., Wang, M., Ham, S. W. & Carr, B. I. H32, a nonquinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK. Cancer Biol. Ther. 5, 1340-1347 (2006).
143. Blanchard, J. L., Epstein, D. M., Boisclair, M. D., Rudolph, J. & Pal, K. Dysidiolide and related γ-hydroxy butenolide compounds as inhibitors of the protein tyrosine phosphatase, CDC25. Bioorg. Med. Chem. Lett. 9, 2537-2538 (1999).
144. Ham, S. W. et al. Naphthoquinone analogs as inactivators of cdc25 phosphatase. Bioorg. Med. Chem. Lett. 8, 2507-2510 (1998).
145. Wrobel, J. et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2, 3-d]furans and 11-arylbenzo[b]naphtho[2, 3-d]thiophenes. J. Med. Chem. 42, 3199-3202 (1999).
146. Tamura, K. et al. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res. 60, 1317-1325 (2000).
147. Sohn, J. & Rudolph, J. Catalytic and chemical competence of regulation of cdc25 phosphatase by oxidation/reduction. Biochemistry 42, 10060-10070 (2003).
148. Kar, S., Wang, M., Ham, S. W. & Carr, B. I. Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK. Biochem. Pharmacol. 72, 1217-1227 (2006).
149. Mondesert, O. et al. A fission yeast strain expressing human CDC25A phosphatase: a tool for selectivity studies of pharmacological inhibitors of CDC25. Curr. Genet. 45, 283-288 (2004).
150. Brezak, M. C. et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res. 64, 3320-3325 (2004).
151. Kar, S., Wang, M., Yao, W., Michejda, C. J. & Carr, B. I. PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol. Cancer Ther. 5, 1511-1519 (2006).
152. Rudolph, J. Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases. Nature Rev. Cancer 7, 202-211 (2007).
153. Cazales, M. et al. Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly. Mol. Cancer Ther. 6, 318-325 (2007).
154. Cheon, H. G., Kim, S. M., Yang, S. D., Ha, J. D. & Choi, J. K. Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent. Eur. J. Pharmacol. 485, 333-339 (2004).
155. Collins, I. & Workman, P. New approaches to molecular cancer therapeutics. Nature Chem. Biol. 2, 689-700 (2006).
156. Chen, Z. et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer 119, 2784-2794 (2006).
157. Syljuasen, R. G. et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell Biol. 25, 3553-3562 (2005).
158. Matthews, D. J. et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6, 104-110 (2007).
159. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 687-688 (2006).
160. Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673-4680 (1994).
161. Retief, J. D. Phylogenetic analysis using PHYLIP. Methods Mol. Biol. 132, 243-258 (2000).
162. van Vugt, M. A., Bras, A. & Medema, R. H. Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res. 65, 7037-7040 (2005).
163. Broggini, M. et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 20, 4835-4840. (2000).
164. Kieffer, I., Lorenzo, C., Dozier, C. & Ducommun, B. Differential mitotic degradation of the CDC25B variants. Oncogene 2007 (in the press).